Shin Nippon Biomedical Laboratories, Ltd. (TYO:2395)
Japan · Delayed Price · Currency is JPY 1,481.00
-6.00 (-0.40%)
Aug 12, 2026, 3:15 PM JST
TYO:2395 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 33,916 | 32,524 | 32,413 | 26,450 | 25,090 | 17,748 | |
Revenue Growth | 1.72% | 0.34% | 22.54% | 5.42% | 41.37% | 17.46% |
Cost of Revenue | 18,700 | 16,287 | 15,453 | 12,168 | 12,044 | 8,061 |
Gross Profit | 15,217 | 16,237 | 16,960 | 14,282 | 13,046 | 9,687 |
Selling, General & Admin | 8,845 | 10,731 | 11,062 | 8,116 | 6,830 | 4,908 |
Research & Development | 2,400 | 2,400 | 2,217 | 1,741 | 683 | 425 |
Operating Expenses | 11,700 | 13,584 | 13,975 | 10,120 | 7,801 | 5,491 |
Operating Income | 3,517 | 2,653 | 2,985 | 4,162 | 5,245 | 4,196 |
Interest Expense | -342.34 | -293 | -202 | -138 | -125 | -126 |
Interest & Investment Income | 244.63 | 239 | 98 | 188 | 58 | 8 |
Earnings From Equity Investments | 2,886 | 2,780 | 3,513 | 2,751 | 2,489 | 1,439 |
Currency Exchange Gain (Loss) | 203.98 | 152 | -162 | 60 | 1,511 | 1,370 |
Other Non Operating Income (Expenses) | 1,108 | 302 | 217 | -7 | 16 | 190 |
EBT Excluding Unusual Items | 7,617 | 5,833 | 6,449 | 7,016 | 9,194 | 7,077 |
Gain (Loss) on Sale of Investments | -3 | -3 | -131 | 51 | -1,327 | 1,381 |
Gain (Loss) on Sale of Assets | -438.48 | -437 | -228 | -50 | -13 | -21 |
Asset Writedown | 147.37 | -11 | -78 | -34 | -44 | -225 |
Other Unusual Items | - | 865 | - | -9 | -51 | -30 |
Pretax Income | 7,322 | 6,247 | 6,012 | 6,974 | 7,759 | 8,182 |
Income Tax Expense | 1,982 | 1,713 | 1,148 | 1,456 | 1,708 | 1,016 |
Earnings From Continuing Operations | 5,341 | 4,534 | 4,864 | 5,518 | 6,051 | 7,166 |
Minority Interest in Earnings | 29.61 | 32 | 60 | 13 | 9 | -39 |
Net Income | 5,370 | 4,566 | 4,924 | 5,531 | 6,060 | 7,127 |
Net Income to Common | 5,370 | 4,566 | 4,924 | 5,531 | 6,060 | 7,127 |
Net Income Growth | 6.07% | -7.27% | -10.97% | -8.73% | -14.97% | 94.67% |
Shares Outstanding (Basic) | 42 | 42 | 42 | 42 | 42 | 42 |
Shares Outstanding (Diluted) | 42 | 42 | 42 | 42 | 42 | 42 |
Shares Change | - | - | - | - | -0.00% | - |
EPS (Basic) | 129.00 | 109.68 | 118.28 | 132.86 | 145.56 | 171.19 |
EPS (Diluted) | 129.00 | 109.68 | 118.28 | 132.86 | 145.56 | 171.19 |
EPS Growth | 6.07% | -7.27% | -10.97% | -8.73% | -14.97% | 94.67% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 3,154 | -3,818 | -6,476 | -834 | 4,410 |
Free Cash Flow Per Share | - | 75.76 | -91.71 | -155.56 | -20.03 | 105.93 |
Dividend Per Share | 50.000 | 50.000 | 50.000 | 50.000 | 50.000 | 30.000 |
Dividend Growth | 0% | 0% | 0% | 0% | 66.67% | 200.00% |
Gross Margin | 44.87% | 49.92% | 52.33% | 54.00% | 52.00% | 54.58% |
Operating Margin | 10.37% | 8.16% | 9.21% | 15.73% | 20.91% | 23.64% |
Profit Margin | 15.83% | 14.04% | 15.19% | 20.91% | 24.15% | 40.16% |
Free Cash Flow Margin | - | 9.70% | -11.78% | -24.48% | -3.32% | 24.85% |
EBITDA | 7,154 | 6,084 | 5,595 | 6,029 | 6,845 | 5,373 |
EBITDA Margin | 21.09% | 18.71% | 17.26% | 22.79% | 27.28% | 30.27% |
D&A For EBITDA | 3,637 | 3,431 | 2,610 | 1,867 | 1,600 | 1,177 |
EBIT | 3,517 | 2,653 | 2,985 | 4,162 | 5,245 | 4,196 |
EBIT Margin | 10.37% | 8.16% | 9.21% | 15.73% | 20.91% | 23.64% |
Effective Tax Rate | 27.06% | 27.42% | 19.10% | 20.88% | 22.01% | 12.42% |